Introduction

44
A great deal of evidence implicates the serotonin (5HT) 45 system dysfunction in psychiatric diseases, particularly in the 46 two major psychotic diseases, Schizophrenia (SCZ) and 47 Bipolar disorders (BPD) (Lesch, 1998) . 5HTR1A is an impor-48 tant subtype of 5HT receptors, widely distributed in the brain, 49 especially in the cortico-limbic regions receiving serotonin-50 ergic input from the raphe nuclei (Lesch and Gutknecht, 51 2004). These receptors also serve as somato-dendritic auto-52 receptors controlling the firing rate of the 5HT neuron (Blier 53 and de Montigny, 1987) . Alteration of these receptors has 54 been reported in both BPD and SCZ, mostly (but not always) 55 with decrease in either binding levels of 5HTR1a in the cortex 56 or in 5HTR1A mRNA levels (Gray et al., 2006; Lopez-Figueroa 57 et al., 2004) . Genetic studies have also reported association of 58 the 5HTR1A gene variants in bipolar patients (Kishi et al., 59 2011). In particular, pharmacogenetic studies reported that 60 one 5HTR1A gene variant (− 1019 C N G), was associated with 61 drug treatment response in both SCZ (Mossner et al., 2009; 62 Reynolds et al., 2006) and BPD (Benedetti et al., 2004) . To 63 diversify these studies, another approach for assessing 5HT factors (Jaenisch and Bird, 2003) . DNA methylation has been 76 offered as an epigenetic explanation for the discordance of 77 monozygote twins for schizophrenia (Petronis et al., 2003 reliability for the DSM-IV Axis-I disorders (Preisig et al., 1999 
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In our study, there was no effect either of the age, or of the 259 gender.
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This study has used lymphocyte DNA, instead of brain ing inherited epigenetic variation (Rosa et al., 2008) . 
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